Literature DB >> 30941641

T helper 17 (Th17) cells and interleukin-17 (IL-17) in cancer.

Seon Hee Chang1.   

Abstract

Th17 cells are a specialized subset of CD4+ T cells that are essential in driving inflammation during autoimmune disease and infection through a signature cytokine IL-17. Th17 cells have been found in various human cancers. The function of these cells in cancers is highly context-dependent; both tumor-promoting and tumor-suppressing activity have been reported. IL-17 and IL-22, Th17-derived cytokines, influence the tumor microenvironment by directly promoting transformed cell properties and neighboring stromal cell activity. These cytokines are also involved in regulation of the immune system by modulating the activities of myeloid cells and T cells. These findings suggest that Th17 cells and their cytokines are a key mediator of cancer development, representing a potential target for cancer therapy. Herein, I review recent preclinical studies on the function of Th17 cells and IL-17 in cancer and discuss possible therapeutic approaches to harness Th17 cells for cancer immunotherapy.

Entities:  

Keywords:  Cancer; IL-17; Immunotherapy; Inflammation; Oncogene; Th17 cells

Year:  2019        PMID: 30941641     DOI: 10.1007/s12272-019-01146-9

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  16 in total

Review 1.  Th17 cells and their related cytokines: vital players in progression of malignant pleural effusion.

Authors:  Yiran Niu; Qiong Zhou
Journal:  Cell Mol Life Sci       Date:  2022-03-17       Impact factor: 9.261

Review 2.  Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis.

Authors:  Ki Wung Chung; Ye Eun Cho; Seung-Jin Kim; Seonghwan Hwang
Journal:  Arch Pharm Res       Date:  2022-04-07       Impact factor: 4.946

3.  MiR-22 regulated T cell differentiation and hepatocellular carcinoma growth by directly targeting Jarid2.

Authors:  Lian Zhang; Ping Yang; Jing Wang; Qi Liu; Tian Wang; Yaling Wang; Feng Lin
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

Review 4.  Malignant Pleural Effusions-A Window Into Local Anti-Tumor T Cell Immunity?

Authors:  Nicola Principe; Joel Kidman; Richard A Lake; Willem Joost Lesterhuis; Anna K Nowak; Alison M McDonnell; Jonathan Chee
Journal:  Front Oncol       Date:  2021-04-27       Impact factor: 6.244

5.  Distinct hepatic immunological patterns are associated with the progression or inhibition of hepatocellular carcinoma.

Authors:  Faridoddin Mirshahi; Hussein F Aqbi; Madison Isbell; Saeed H Manjili; Chunqing Guo; Mulugeta Saneshaw; Dipankar Bandyopadhyay; Mikhail Dozmorov; Archit Khosla; Katy Wack; Oscar M Carrasco-Zevallos; Michael O Idowu; Xiang-Yang Wang; Arun J Sanyal; Masoud H Manjili
Journal:  Cell Rep       Date:  2022-03-01       Impact factor: 9.995

Review 6.  Lung Cancer Heterogeneity in Modulation of Th17/IL17A Responses.

Authors:  Dominique Armstrong; Cheng-Yen Chang; Donald R Lazarus; David Corry; Farrah Kheradmand
Journal:  Front Oncol       Date:  2019-12-10       Impact factor: 6.244

7.  The Effect of Different Immunization Cycles of a Recombinant Mucin1-Maltose-Binding Protein Vaccine on T Cell Responses to B16-MUC1 Melanoma in Mice.

Authors:  Hongyue Zhou; Zenan Zhang; Guomu Liu; Mengyu Jiang; Jingjing Wang; Yu Liu; Guixiang Tai
Journal:  Int J Mol Sci       Date:  2020-08-13       Impact factor: 5.923

8.  Network Pharmacology-Oriented Identification of Key Proteins and Signaling Pathways Targeted by Xihuang Pill in the Treatment of Breast Cancer.

Authors:  Jiafa Wu; Dongping Luo; Shengnan Li
Journal:  Breast Cancer (Dove Med Press)       Date:  2020-12-08

9.  Systemic Profiling of KDM5 Subfamily Signature in Non-Small-Cell Lung Cancer.

Authors:  Fang Hao
Journal:  Int J Gen Med       Date:  2021-10-27

Review 10.  Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.

Authors:  Eric de Sousa; Joana R Lérias; Antonio Beltran; Georgia Paraschoudi; Carolina Condeço; Jéssica Kamiki; Patrícia Alexandra António; Nuno Figueiredo; Carlos Carvalho; Mireia Castillo-Martin; Zhe Wang; Dário Ligeiro; Martin Rao; Markus Maeurer
Journal:  Front Immunol       Date:  2021-07-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.